Amazon cover image
Image from Amazon.com

Devalued and Distrusted : Can the Pharmaceutical Industry Restore Its Broken Image? / John L. LaMattina, PhD.

By: Material type: TextTextPublisher number: EB00063788 | Recorded BooksPublication details: Hoboken, New Jersey : Wiley, [2013]Description: 1 online resource (ix, 125 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781118487471
  • 1118487478
  • 9781283917421
  • 1283917424
  • 9781118511251
  • 1118511255
  • 9781118511299
  • 1118511298
  • 9781118511329
  • 1118511328
Subject(s): Genre/Form: Additional physical formats: Print version:: Devalued and distrusted.DDC classification:
  • 338.4/76151 23
LOC classification:
  • HD9665.5 .L36 2013eb
Online resources:
Contents:
1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.
Summary: "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Provided by publisher.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Includes index.

Machine generated contents note: Introduction Part 1. "The 4 secrets that drug companies don't want you to know" part 2. What has happened to R & D productivity? a. impact of mergers b. impact of FDA c. impact of payers Part 3. Challenges in key therapeutic areas for improving health a. cancer b. diseases of the brain c. cardiovascular disease d. diabetes e. bacterial Infections part 4. Improving R & D output a. view of others b. personal vision part 5. Restoring the pharma image part 6. Final thoughts.

Print version record.

"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Provided by publisher.

Includes bibliographical references and index.

1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.

Public Health